Stock Track | Kiniksa Pharmaceuticals Plunges 6.53% Pre-Market on Q3 Earnings Miss

Stock Track10-28

Kiniksa Pharmaceuticals Ltd. (KNSA) stock tumbled 6.53% in pre-market trading on Tuesday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's earnings fell short of analyst expectations, despite beating revenue estimates.

Kiniksa reported earnings per share (EPS) of $0.23 for Q3 2025, missing the FactSet estimate of $0.32. This earnings miss appears to be the primary driver behind the stock's significant pre-market decline. However, the company's sales performance was more positive, with reported revenue of $180.855 million surpassing the estimated $167.358 million.

Despite the market's negative reaction, Kiniksa shared some optimistic projections. The company expects its 2025 Arcalyst net product revenue to be between $670 million and $675 million. Additionally, Kiniksa anticipates remaining cash flow positive on an annual basis under its current operating plan. The firm also reported progress in its product pipeline, stating it's on track for Phase 2 data from the dose-focusing portion of the KPL-387 Phase 2/3 recurrent pericarditis trial in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105135388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105135388","market":"sg","top_or_hot":-1,"title":"Stock Track | Kiniksa Pharmaceuticals Plunges 6.53% Pre-Market on Q3 Earnings Miss","media":"Stock Track","content":"<p>Kiniksa Pharmaceuticals Ltd. (KNSA) stock tumbled 6.53% in pre-market trading on Tuesday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's earnings fell short of analyst expectations, despite beating revenue estimates.</p>\n\n<p>Kiniksa reported earnings per share (EPS) of $0.23 for Q3 2025, missing the FactSet estimate of $0.32. This earnings miss appears to be the primary driver behind the stock's significant pre-market decline. However, the company's sales performance was more positive, with reported revenue of $180.855 million surpassing the estimated $167.358 million.</p>\n\n<p>Despite the market's negative reaction, Kiniksa shared some optimistic projections. The company expects its 2025 Arcalyst net product revenue to be between $670 million and $675 million. Additionally, Kiniksa anticipates remaining cash flow positive on an annual basis under its current operating plan. The firm also reported progress in its product pipeline, stating it's on track for Phase 2 data from the dose-focusing portion of the KPL-387 Phase 2/3 recurrent pericarditis trial in the second half of 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kiniksa Pharmaceuticals Plunges 6.53% Pre-Market on Q3 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kiniksa Pharmaceuticals Plunges 6.53% Pre-Market on Q3 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-28 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kiniksa Pharmaceuticals Ltd. (KNSA) stock tumbled 6.53% in pre-market trading on Tuesday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's earnings fell short of analyst expectations, despite beating revenue estimates.</p>\n\n<p>Kiniksa reported earnings per share (EPS) of $0.23 for Q3 2025, missing the FactSet estimate of $0.32. This earnings miss appears to be the primary driver behind the stock's significant pre-market decline. However, the company's sales performance was more positive, with reported revenue of $180.855 million surpassing the estimated $167.358 million.</p>\n\n<p>Despite the market's negative reaction, Kiniksa shared some optimistic projections. The company expects its 2025 Arcalyst net product revenue to be between $670 million and $675 million. Additionally, Kiniksa anticipates remaining cash flow positive on an annual basis under its current operating plan. The firm also reported progress in its product pipeline, stating it's on track for Phase 2 data from the dose-focusing portion of the KPL-387 Phase 2/3 recurrent pericarditis trial in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"","article_id":"1105135388","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105135388","pubTimestamp":1761652994,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kiniksa Pharmaceuticals Ltd. (KNSA) stock tumbled 6.53% in pre-market trading on Tuesday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"个股追踪|Kiniksa Pharmaceuticals因Q3盈利未达预期盘前暴跌6.53%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Kiniksa Pharmaceuticals Ltd. (KNSA) stock tumbled 6.53% in pre-market trading on Tuesday following the release of its third-quarter 2025 financial results. The biopharmaceutical company's earnings fell short of analyst expectations, despite beating revenue estimates.\nKiniksa reported earnings per share (EPS) of $0.23 for Q3 2025, missing the FactSet estimate of $0.32. This earnings miss appears to be the primary driver behind the stock's significant pre-market decline. However, the company's sales performance was more positive, with reported revenue of $180.855 million surpassing the estimated $167.358 million.\nDespite the market's negative reaction, Kiniksa shared some optimistic projections. The company expects its 2025 Arcalyst net product revenue to be between $670 million and $675 million. Additionally, Kiniksa anticipates remaining cash flow positive on an annual basis under its current operating plan. The firm also reported progress in its product pipeline, stating it's on track for Phase 2 data from the dose-focusing portion of the KPL-387 Phase 2/3 recurrent pericarditis trial in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105135388","isCrawlerRequest":true}